A5010636453- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Brain Metastases and Treatment
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- Sexual Assault and Victimization Studies
- Workplace Violence and Bullying
- Colorectal Cancer Treatments and Studies
- Nanoplatforms for cancer theranostics
- Synthesis and biological activity
- Virus-based gene therapy research
- Computational Drug Discovery Methods
- Radiopharmaceutical Chemistry and Applications
- Sarcoidosis and Beryllium Toxicity Research
- Lanthanide and Transition Metal Complexes
- Protein Degradation and Inhibitors
- Diversity and Career in Medicine
- Autoimmune and Inflammatory Disorders Research
- RNA Interference and Gene Delivery
- Immune cells in cancer
- Photodynamic Therapy Research Studies
- Cancer-related cognitive impairment studies
- Medical Imaging Techniques and Applications
Universitair Ziekenhuis Brussel
2020-2024
Vrije Universiteit Brussel
2020-2024
Ghent University
2021
Geneeskundige en Gezondheidsdienst
2021
Background Patients with recurrent glioblastoma (rGB) have a poor prognosis median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous administration programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors has low activity patients rGB. In this phase I trial, intracerebral (IC) ipilimumab (IPI) nivolumab (NIVO) combination intravenous NIVO was investigated. Methods Within 24 hours following the fixed dose (10 mg) NIVO, underwent...
Background: Pembrolizumab improves the survival of patients with advanced melanoma. A comprehensive analysis baseline variables that predict benefit pembrolizumab monotherapy has not been conducted. Methods: Survival data melanoma who were treated in a single university hospital collected. multivariate Cox regression was performed to correlate clinical, laboratory, and radiologic characteristics NanoString IO360 gene expression profiling (GEP) survival. Results: 183 included (stage IV 85.2%,...
Patients with
Background Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals enhancing release antigens that can be captured processed by CD1c (BDCA-1) + / CD141 (BDCA-3) myDCs, order to reinvigorate cancer-immunity cycle. Methods In this phase I trial,...
Focal radiation necrosis of the brain (fRNB) is a late adverse event that can occur following treatment benign or malignant lesions with stereotactic therapy (SRT) radiosurgery (SRS). Recent studies have shown incidence fRNB higher in cancer patients who received immune checkpoint inhibitors. The use bevacizumab (BEV), monoclonal antibody targets vascular endothelial growth factor (VEGF), an effective for when given at dose 5–7.5 mg/kg every two weeks. In this single-center retrospective...
Patients with advanced melanoma who progress after treatment immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if BRAF V600 mutated) have no remaining effective options. The presence of CD1c (BDCA-1)+ CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in the tumor microenvironment correlates pre-existing recognition responsiveness to checkpoint blockade. synthetic saponin-based adjuvant AS01B enhances adaptive immunity through involvement myDC. In this first-in-human phase I clinical...
Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in re-licensing antitumor cytotoxic T lymphocytes. IT injection of the IgG1 monoclonal antibodies ipilimumab and avelumab may induce antibody-dependent cellular cytotoxicity, thereby enhancing release tumor antigens that can be captured processed by CD1c (BDCA-1)+ myDCs. Patients with advanced solid tumors after standard care were eligible for injections ≥1 lesion (10 mg) (40 intravenous (IV) nivolumab on day 1, followed...
Optimal dosing and duration of adjuvant treatment with PD-1 CTLA-4 immune checkpoint inhibitors have not been established. Prior to their regulatory approval we investigated a low-dose regimen nivolumab or without ipilimumab in sequential dual-cohort phase II clinical trial.
Patients with advanced BRAFV600 mutant melanoma who progressed on prior treatment BRAF-/MEK-inhibitors and programmed cell death 1 or cytotoxic T-lymphocyte-associated antigen 4 immune checkpoint inhibitors can benefit from retreatment the combination of a BRAF- MEK-inhibitor (‘rechallenge’). Hydroxychloroquine prevent autophagy-driven resistance improve efficacy in preclinical models. This clinical trial investigated use combined BRAF-/MEK-inhibition dabrafenib trametinib plus...
Melanoma patients failing all approved treatment options have a poor prognosis. The antimelanoma activity of regorafenib (REGO), multitargeted kinase inhibitor, has not been investigated in this patient population. objective response rate and safety REGO advanced melanoma was retrospectively. Twenty-seven received treatment. All had progressed on anti–programmed cell death protein 1 (PD-1) anti–cytotoxic T-lymphocyte–associated 4 (CTLA-4) checkpoint inhibition BRAF/MEK inhibitors (in case...
Abstract Background Sexual violence has globally been recognized as harmful to young people’s health. In medical school, which is a highly competitive environment, the risk supposedly even bigger. this study we firstly aimed investigate magnitude and precipitating factors of sexual in students specialty registrars Flanders, Belgium. Secondly, wanted assess reactive behaviours well knowledge possible types bystander reactions potential support resources for victims violence. Methods This was...
Background: MEK-inhibitor monotherapy has activity in advanced NRASQ61R/K/L mutant melanoma but is associated with dose-limiting cutaneous toxicity. The combination of a BRAF- at their full dose (as BRAFV600E/K melanoma) low It unknown whether BRAF-inhibitor can mitigate the skin toxicity full-dose treatment patients melanoma. Methods: This two-stage phase 2 clinical trial investigated trametinib mg once daily who were pretreated immune checkpoint inhibitors. In case trametinib-related...
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly systemic anti-tumor effect seen following intratumoral injection have not yet been studied but are likely to be mediated by myeloid dendritic cells (myDC) initiate an adaptive immune response. In this study we could demonstrate T-VEC non-toxic human myDC. and oncolysate melanoma cell lines were able mature myDC take up lysed cross-present melanoma-derived tumor antigens...
e14003 Background: there are no active treatment options available for patients (pts) diagnosed with melanoma brain metastases (MBM) that progress despite immune checkpoint inhibitors (ICI), and BRAF-/MEK-inhibitors (BRAF/MEKi) in pts BRAF V600mutant melanoma. Regorafenib (REGO), an oral multi-target kinase inhibitor, including potent inhibition of RAF-dimers, has single-agent activity pretreated (AS Vander Mijnsbrugge et al. SMR 2022). Here we report our single-institution experience REGO...
Treatment with combined BRAF and MEK inhibition is widely accepted as a first-line treatment option for patients advanced V600E mutant melanoma. It generally well-tolerated has limited side-effects. However, we report case of sarcoid-like syndrome induced by dabrafenib/trametinib (D/T) in patient stage IV-M1d Sarcoid-like known side-effect immune checkpoint-inhibition therapy but only rarely been described BRAF/MEK inhibition. recognizing this important because potential misinterpretation...
9529 Background: The mitogen-activated protein kinase (MAPK) pathway can be activated by alternative driver mutations in BRAF V600 / NRAS Q61R/K/L wild-type (wt) melanoma. MEK-inhibitor monotherapy has activity wt melanoma, but is associated with considerate skin toxicity. Skin toxicity the trametinib (T) effectively mitigated adding a low dose (50 mg BID) of BRAF-inhibitor dabrafenib (LD-D) (Awada et al. Ann Oncol 2020). Methods: This two-stage, single-center phase 2 trial investigated T QD...
2033 Background: Intracerebral administration of ipilimumab (IPI) and nivolumab (NIVO) following resection rGB was demonstrated to be safe resulted in encouraging survival (Duerinck, Schwarze et al. JITC 2021; Neyns ESMO 2021). CD1c(BDCA-1) + CD141(BDCA-3) myDC play a pivotal role initiating an adaptive anti-tumor immune response by re-licensing cytotoxic T lymphocytes within the tumor microenvironment. Methods: Eligible patients (pts)(diagnosed with radiation temozolomide treatment; not...